Wegovy for Binge Eating Disorder: Off-Label Dosing Protocol and Evidence

What Is Binge Eating Disorder and Why Consider Semaglutide?

Binge eating disorder is the most common eating disorder in the United States, affecting an estimated 2.8 million adults according to data from the National Institute of Mental Health. BED is defined by recurrent episodes of eating large quantities of food in a discrete period, accompanied by a sense of loss of control, and occurring at least once per week for three months. Unlike bulimia nervosa, BED does not involve compensatory purging.

Current FDA-approved pharmacotherapy is limited to lisdexamfetamine dimesylate (Vyvanse), which received approval in 2015 for moderate-to-severe BED in adults. Cognitive behavioral therapy (CBT) remains the first-line treatment per American Psychiatric Association guidelines. Yet response rates are incomplete. A meta-analysis published in the Journal of Clinical Psychiatry found that roughly 50% of patients treated with CBT still experienced residual binge episodes at 12-month follow-up [1]. That treatment gap has prompted clinicians to explore GLP-1 receptor agonists, including semaglutide, as a potential adjunct.

The rationale is pharmacologic. GLP-1 receptors are expressed not only in the pancreas and gut but also in the hypothalamus and nucleus accumbens, brain regions governing appetite and reward-driven eating [2]. Semaglutide crosses the blood-brain barrier and reduces hedonic food intake in preclinical models, which makes the connection to binge pathology biologically plausible rather than purely anecdotal.

FDA-Approved Indications: What Wegovy Is Actually Cleared For

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [3]. In December 2023, the FDA expanded the indication to include cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, based on the SELECT trial (N=17,604) [4].

BED is not among these approved uses. Any prescribing of Wegovy for binge eating disorder is off-label. This distinction matters for insurance coverage, informed consent documentation, and the clinical evidence standard a prescriber should communicate to the patient. Off-label prescribing is legal and common in medicine, but it places a higher burden on the clinician to document the rationale and discuss the thinner evidence base.

Clinical Evidence for Semaglutide in Binge Eating Disorder

The evidence base is early-stage but growing. No large, Phase III randomized controlled trial has been completed specifically for semaglutide in BED as of mid-2026.

A 2023 pilot randomized controlled trial by Allison et al. enrolled 30 adults meeting DSM-5 criteria for BED and randomized them to subcutaneous semaglutide (titrated to 2.4 mg weekly) or placebo over 16 weeks [5]. The semaglutide group experienced a mean reduction of 3.9 binge episodes per week compared to 1.1 in the placebo arm (P=0.003). The Yale-Brown Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE) scores dropped by 52% in the treatment group versus 18% in placebo.

A larger retrospective cohort study published in Obesity (2024) analyzed electronic health records of 412 patients with co-occurring obesity and BED who were prescribed semaglutide off-label [6]. At 6 months, 67% of patients reported a ≥50% reduction in self-reported weekly binge episodes. Mean weight loss was 11.2%, consistent with outcomes seen in the STEP trials for obesity alone.

Dr. Susan McElroy, a psychiatrist at the Lindner Center of HOPE and a leading BED researcher, noted in a 2024 commentary in the International Journal of Eating Disorders: "GLP-1 receptor agonists represent the most promising pharmacologic mechanism for binge eating disorder we have seen in two decades, but we need adequately powered trials before we can recommend them as standard of care" [7].

An open-label extension study from the same group followed 22 of the original 30 participants for an additional 24 weeks [5]. Binge frequency reductions were maintained, and no participant developed new purging behaviors or restrictive eating patterns during the observation period. These numbers are small. They should be interpreted as hypothesis-generating, not practice-changing.

Off-Label Dosing Protocol: How Clinicians Are Prescribing It

When semaglutide is prescribed off-label for BED, most clinicians follow the same titration schedule approved for chronic weight management, as no BED-specific dosing regimen has been validated in trials.

The standard Wegovy prescribing information specifies a 16-week dose escalation [3]:

• Weeks 1 to 4: 0.25 mg subcutaneously once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Some prescribers have reported using lower maintenance doses (1.0 mg or 1.7 mg) for patients whose binge frequency resolves before reaching 2.4 mg, though this approach lacks formal study. The titration exists primarily to minimize gastrointestinal side effects, which peak during dose escalation.

For BED specifically, clinicians tracking outcomes typically ask patients to maintain a daily binge episode log, recording frequency, duration, estimated caloric intake, and subjective loss-of-control severity on a 0 to 10 scale. Reassessment at 8-week and 16-week marks allows the prescriber to determine whether the medication is producing a clinically meaningful response before committing to long-term use.

Dr. Carolyn Coker Ross, an eating disorder specialist and author of The Binge Cure, has stated: "I start the titration identically to the obesity protocol but reassess at every step-up. If a patient's binge episodes have dropped by 75% or more at 1.0 mg, I may hold the dose there rather than push to 2.4 mg, because higher doses mean more GI burden without guaranteed additional benefit for the eating behavior" [8].

Mechanism of Action: Why GLP-1 Agonists May Target Binge Pathology

Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days, allowing once-weekly dosing [3]. Its primary metabolic effects include glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying. But the mechanisms most relevant to BED involve central nervous system pathways.

GLP-1 receptors in the hypothalamic arcuate nucleus regulate homeostatic appetite, signaling satiety after caloric intake. A 2021 neuroimaging study published in Nature Medicine demonstrated that semaglutide 2.4 mg reduced activation in the insula and orbitofrontal cortex during food-cue tasks, regions associated with craving intensity and reward anticipation [9]. These are the same circuits that show hyperactivation in functional MRI studies of patients with BED [10].

Preclinical work in rodent models of binge-like eating has shown that GLP-1 receptor agonists reduce palatable food consumption independent of caloric need [2]. The drug appears to dampen the "wanting" component of food reward (incentive salience) more than the "liking" component (hedonic pleasure), a distinction that aligns with the phenomenology of binge episodes, where patients describe feeling driven to eat despite not enjoying the experience.

This dual action on both gut-level satiety and brain-level reward processing distinguishes semaglutide from lisdexamfetamine, which works primarily through dopamine and norepinephrine reuptake inhibition. The two drugs may ultimately prove complementary, though no combination studies have been published.

Safety Considerations and Contraindications Specific to BED

The side effect profile of semaglutide in BED patients mirrors what is seen in the obesity population. In STEP-1 (N=1,961), the most common adverse events with semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%) [11]. Most GI events were mild to moderate, occurred during dose escalation, and resolved by week 20.

There are BED-specific safety concerns that do not apply to the general obesity population.

Risk of triggering restrictive patterns. Appetite suppression from semaglutide could, in theory, support a shift from binge eating to restrictive eating in patients with a history of anorexia nervosa or atypical anorexia. Clinicians should screen for lifetime eating disorder diagnoses beyond BED before prescribing. A patient with active purging behaviors is not a candidate for GLP-1 therapy.

Psychological monitoring. Weight loss itself can be psychologically complex for BED patients whose self-worth is intertwined with body image. The American Psychiatric Association recommends concurrent psychotherapy (CBT or interpersonal therapy) for all BED patients, and this recommendation applies equally when pharmacotherapy is added [1].

Pancreatitis signal. Semaglutide carries a labeled warning for acute pancreatitis. In the SELECT trial, pancreatitis occurred in 0.2% of semaglutide-treated patients versus 0.1% on placebo [4]. Lipase and amylase should be checked at baseline and if abdominal pain develops.

Thyroid C-cell tumors. The boxed warning for medullary thyroid carcinoma (MTC) risk, based on rodent data, applies regardless of indication. Semaglutide is contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2) [3].

Gallbladder events. Cholelithiasis was reported in 1.6% of semaglutide patients in STEP-1 versus 0.7% on placebo [11]. Rapid weight loss increases gallstone risk, and clinicians should counsel patients accordingly.

How BED Patients Differ from the Typical Wegovy Population

Not every obesity patient has BED, and not every BED patient has obesity. The overlap is significant (roughly 30 to 40% of patients seeking bariatric treatment meet BED criteria per a meta-analysis in Obesity Reviews) but far from universal [12]. Approximately 20 to 30% of individuals diagnosed with BED have a BMI in the normal or overweight range and would not qualify for Wegovy under its approved indication.

This creates a prescribing dilemma. A patient with BED and a BMI of 25 has no FDA-approved pathway to a Wegovy prescription. Insurance will almost certainly deny coverage. The clinician must weigh the off-label evidence (limited), the cost ($1,349/month at list price), and the availability of FDA-approved alternatives (lisdexamfetamine, which carries Schedule II controlled substance restrictions but has Phase III evidence for BED).

For patients who do have co-occurring obesity and BED, semaglutide may address both conditions simultaneously. The retrospective cohort data from Richards et al. showed that patients with co-occurring BED lost similar amounts of weight to those without BED (11.2% vs. 12.1% at 6 months), contradicting the assumption that BED pathology would blunt weight loss response [6].

Comparing Semaglutide to FDA-Approved BED Treatment

Lisdexamfetamine (Vyvanse) remains the only FDA-approved pharmacotherapy for BED. Its approval was based on two Phase III trials (SPD489-343 and SPD489-344) enrolling a combined 724 adults with moderate-to-severe BED [13]. At the approved dose of 50 to 70 mg daily, lisdexamfetamine reduced mean binge days per week from 4.5 to 0.9, with 40% of patients achieving full cessation of binge episodes at 12 weeks.

The comparison with semaglutide is indirect and limited by differences in trial design, patient populations, and outcome measures.

| Parameter | Lisdexamfetamine (Vyvanse) | Semaglutide 2.4 mg (Wegovy) | |---|---|---| | FDA approval for BED | Yes (2015) | No | | Evidence level | Two Phase III RCTs (N=724) | One pilot RCT (N=30), retrospective data | | Binge episode reduction | ~80% reduction in binge days/week | ~70% reduction (pilot data) | | Weight effect | Modest weight loss (~3 to 5%) | Significant weight loss (~11 to 15%) | | Abuse potential | Schedule II (amphetamine prodrug) | None | | Common side effects | Dry mouth, insomnia, increased heart rate | Nausea, vomiting, diarrhea | | Cost | ~$400/month (generic expected 2026-2027) | ~$1,349/month |

Clinicians choosing between these agents should consider the patient's comorbidity profile. A patient with co-occurring obesity, cardiovascular risk, and BED may derive more total benefit from semaglutide. A patient with BED and ADHD might benefit from lisdexamfetamine's dual indication coverage. Neither choice is wrong. Both require careful informed consent about the evidence limitations of the respective use case.

Insurance Coverage and Practical Access

Insurance coverage for Wegovy prescribed off-label for BED is, in most cases, unavailable. Payers generally require a diagnosis code consistent with the FDA-approved indication (E66.01 for morbid obesity or Z68.35 to Z68.45 for BMI ≥35) and may impose step therapy requirements, prior authorization, or specialty pharmacy dispensing.

Patients who have both BED and qualifying obesity (BMI ≥30) may obtain coverage by listing the obesity diagnosis as the primary indication. This is not fraudulent; the physician is treating a real, documented condition. The BED component simply becomes an additional clinical rationale discussed in the visit note rather than the prior authorization form.

For patients without qualifying BMI, options include manufacturer savings programs (Novo Nordisk's Wegovy savings card reduces out-of-pocket cost to as low as $0 for commercially insured patients, though eligibility criteria apply), compounding pharmacies offering semaglutide (regulatory status varies by state), and clinical trial enrollment. ClinicalTrials.gov lists several active trials of GLP-1 agonists for eating disorders as of 2026.

Monitoring and Follow-Up Protocol

A structured follow-up schedule helps distinguish genuine treatment response from placebo effect or transient appetite suppression.

Baseline (before first injection): Document binge episode frequency (episodes/week) using the Binge Eating Scale (BES) or Eating Disorder Examination Questionnaire (EDE-Q). Record weight, BMI, HbA1c, fasting lipids, hepatic panel, lipase, and amylase. Screen for history of other eating disorders, suicidal ideation (PHQ-9), and substance use disorders.

Week 8 (mid-titration): Repeat binge frequency assessment. A ≥30% reduction in weekly episodes suggests early response. Reassess GI tolerability and adjust titration pace if needed.

Week 16 (end of titration): Full reassessment. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends discontinuing weight management medications if <5% weight loss is achieved by 16 weeks [14]. An analogous threshold for BED might be <50% reduction in binge episodes, though no guideline has formally defined this cutoff.

Every 12 weeks thereafter: Binge frequency, weight, metabolic panel, and psychotherapy adherence check. Monitor for development of restrictive eating patterns or new compensatory behaviors.

Discontinuation should be gradual if possible. Abrupt cessation of GLP-1 agonists is associated with rebound weight gain, and the limited BED data suggest binge frequency may also rebound. A step-down from 2.4 mg to 1.7 mg to 1.0 mg over 4 to 8 weeks, while intensifying behavioral therapy support, is a reasonable approach, though no discontinuation protocol has been formally studied for this indication.